About YUMAB GmbH

Sponsor retains sole responsibility for content.

YUMAB is a German biotech company that provides the discovery and development of fully human antibodies from world’s largest, natural derived, universal, human antibody libraries (>10e11) and patient specific libraries in combination with powerful in vitro selection technologies. YUMAB’s antibody platform is based on more than 28 years of research and development in recombinant antibody technologi...

YUMAB is a German biotech company that provides the discovery and development of fully human antibodies from world’s largest, natural derived, universal, human antibody libraries (>10e11) and patient specific libraries in combination with powerful in vitro selection technologies. YUMAB’s antibody platform is based on more than 28 years of research and development in recombinant antibody technologies by its founders. With this platform YUMAB generates antibody candidates with natural, close to germ-line sequences for lowest immunogenicity and with pre-designed properties (e.g., interspecies X-reactivity, large epitope coverage or targeted epitopes). The candidates are highly developable into several antibody drug formats like full-length IgGs, Fabs, scFvs, bispecifics, chimeric antigen receptors (CARs), fusion proteins, and antibody drug conjugates (ADCs). YUMAB provides customized solutions from target discovery and production, personalized antibody libraries, optimized antibody discovery strategies (also directly on cells) to close to germline antibody engineering and lead development with high success-rates even to difficult targets like GPCRs. YUMAB offers flexible business models from fee-for-service solutions to collaborative projects. Services are not limited to therapeutic development – it also contains recombinant antibody development for next-generation research and for diagnostic applications.

Contact YUMAB GmbH

Phone Number
+49 531 3804 270

More About YUMAB GmbH

Therapeutic Areas
  • Autoimmune disorders
  • Infectious
  • Metabolic
  • Oncology
Technologies
  • Biologics
  • Diagnostics
  • Drug delivery
  • Vaccines
Company Type
  • Biotechnology – Therapeutics
State of Ownership
  • Private
Sponsorship Group
  • Networker
Go to the profile of Andrew Marshall

Andrew Marshall

Chief Editor, Nature Biotechnology, Nature Publishing Group

0 Contributions
47 Followers
0 Following
Go to the profile of Christine Borowski

Christine Borowski

Chief Editor, Nature Medicine, Nature Publishing Group

0 Contributions
47 Followers
0 Following
Go to the profile of Claire Thompson

Claire Thompson

Global Manager, Business Development, Nature Publishing Group

0 Contributions
59 Followers
79 Following
Go to the profile of Raveena Bhambra

Raveena Bhambra

Editor, BioPharma Dealmakers , Nature Publishing Group

29 Contributions
97 Followers
21 Following
Go to the profile of Peter Kirkpatrick

Peter Kirkpatrick

Chief Editor, Nature Reviews Drug Discovery, Nature Publishing Group

2 Contributions
58 Followers
3 Following
Go to the profile of Samia Burridge

Samia Burridge

Business Development Manager, Sponsorship, Springer Nature

5 Contributions
88 Followers
1000 Following
Go to the profile of Veronica Zacatenco

Veronica Zacatenco

Business Development Executive, Nature Publishing Group

1 Contributions
52 Followers
87 Following
4 Contributions
56 Followers
0 Following
1 Contributions
55 Followers
4 Following
1 Contributions
42 Followers
0 Following
24 Contributions
99 Followers
23 Following
1 Contributions
45 Followers
0 Following
1 Contributions
44 Followers
0 Following
Go to the profile of GSK

GSK

3 Contributions
48 Followers
0 Following
3 Contributions
43 Followers
0 Following
Go to the profile of Georgia Francis

Georgia Francis

Editorial Assistant, BioPharm Dealmakers, Nature Publishing Group

0 Contributions
37 Followers
12 Following
Go to the profile of Carmen Ramirez

Carmen Ramirez

Sales Account Executive, Springer Nature

1 Contributions
48 Followers
1000 Following
2 Contributions
8 Followers
26 Following
2 Contributions
9 Followers
22 Following
2 Contributions
10 Followers
23 Following
2 Contributions
9 Followers
23 Following
2 Contributions
6 Followers
6 Following
2 Contributions
9 Followers
24 Following
2 Contributions
9 Followers
0 Following